.Monopar Therapeutics is actually recovering a medicine from the dump of AstraZeneca’s rare disease pipeline. It has actually licensed ALXN-1840, an applicant for the procedure
Read moreAN 2 halves head count, quits period 3 test after records dissatisfy
.AN2 Rehabs is reconsidering its business in feedback to uninspired midphase data, vowing to lay off half its staff members as well as quit a
Read moreALX’s fizzling CD47 reaction price sends out inventory spiraling down
.ALX Oncology’s period 2 stomach cancer cells action price has damaged. After seeing its CD47 blocker easily beat command over the very first one-half of
Read moreAC Immune sees ‘landmark’ possible in Alzheimer’s medication data
.After much more than 20 years of work on neurodegenerative health conditions, Swiss biotech AC Invulnerable insurance claims it could possibly have a video game
Read more